The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Commentary|Articles|March 21, 2025
Emerging ADCs, Biomarker-Driven Treatments, and Diagnostic Advancements Take Center Stage at the SGO Annual Meeting
Author(s)Courtney Flaherty
Fact checked by: Ashling Wahner
Experts reflect on pivotal data, emerging agents, and highly-anticipated trends in gynecologic cancer care discussed during the 2025 SGO Annual Meeting.
Advertisement
Advertisement
The
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.
The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.
Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Advertisement
Advertisement